EyeGate is developing and commercializing products for treating diseases and disorders of the eye. The Companyâs products are based on two proprietary platform technologies: EyeGateâs first platform is based on a cross-linked thiolated carboxymethyl hyaluronic acid (âCMHA-Sâ), a modified form of the natural polymer hyaluronic acid (âHAâ), which is a gel that possesses unique physical and chemical properties including hydration and healing when applied to the ocular surface. The ability of CMHA-S to protect and adhere longer to the ocular surface, and resist degradation makes it well-suited for treating various ocular surface injuries. EGP-437, EyeGateâs second product in clinical trials, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate that is delivered into the ocular tissues through EyeGateâs proprietary innovative drug delivery system, the EyeGate II Delivery System. EGP-437 is currently in trials for the treatment of uveitis and pain and inflammation following cataract surgery. EyeGate has granted a subsidiary of Valeant Pharmaceuticals an exclusive worldwide license to the product in these indications. Source
No articles found.
Sunesis is a biopharmaceutical company focused on the development and commercializ...
Sunesis is a biopharmaceutical company focused ...
CAVU Biotherapies offers a comprehensive solution to prepare for, monitor, and tre...
CAVU Biotherapies offers a comprehensive soluti...
Spark Therapeutics, a fully integrated company, strives to challenge the inevitabi...
Spark Therapeutics, a fully integrated company,...
Iterum Therapeutics plc is an Ireland-based clinical-stage pharmaceutical company ...
Iterum Therapeutics plc is an Ireland-based cli...
Geron is a late-stage clinical biopharmaceutical company focused on the developmen...
Geron is a late-stage clinical biopharmaceutica...
Alimera Sciences (NASDAQ: ALIM), founded in June 2003, is a pharmaceutical company...
Alimera Sciences (NASDAQ: ALIM), founded in Jun...
Join the National Investor Network and get the latest information with your interests in mind.